Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Effect of betahistine on tinnitus and vertigo in cerebrovascular patients (CROSBI ID 511986)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Runjić, Nađa ; Kramarić, Vesna Effect of betahistine on tinnitus and vertigo in cerebrovascular patients // Neurologia Croatica Proceedings / Barac, Boško (ur.). Zagreb, 2005. str. 131-x

Podaci o odgovornosti

Runjić, Nađa ; Kramarić, Vesna

engleski

Effect of betahistine on tinnitus and vertigo in cerebrovascular patients

The aim of this study was to investigate the effect of betahistine dihydrochloride (Betaserc) on tinnitus and vertigo in cerebrovascular patients. Patients and methods: Twenty persons with cochlear tinnitus and central vestibular vertigo, ages 30-60 years ( mean age 48, 70 years) were tested. Control group consisted of 15 patients matched by age, gender, cerebrovacular status, audiological and vestibular findings ( mean age 45, 60 years). The complete otoneurological diagnostics, including doppler flow imaging and electronystagmography was performed before and after the therapy. After the diagnostic evaluation subjects were treated by peroral Betaserc administrated 16 mg three times daily for eight weeks. Ten patients were also included in functional therapy of tinnitus according to the verbotonal method of Petar Guberina using the SUVAG apparatus for masking the tinnitus. Data were analysed by ANOVA statistics. The average period of dizziness duration before the diagnostic evaluation is 3, 2 months (5 days- 2 years), for tinnitus 8 months ( 1 month- 3 years). The leading risk factors for cerebrovascular disease, hypertension, diabetes and hyperlipidaemia were found in all 35 patients ( hypertension in 5 patients, diabetes in 3 patients, hyperlipidaemia in 7 patients, hypertension + hyperlipidaemia in 11, all three factors in 4 patients). After Betaserc treatment, the severity of dizziness and occurrence of nausea significantly reduced (p= 0.005 ; p=0.001). In electronystagmographic evaluation pathological visuo-oculomotor reactions and pathological cervical test results disappeared in 14 of 20 patients, smooth pursuit improved in 16 patients, and cervical nystagmus disappeared in 14 patients. Tinnitus disapeared in only 6 patients, those included in functional therapy of tinnitus, with &laquo ; diagnostic window&raquo ; of 2 months. Results indicate Betaserc as an effective therapy in patients with central vestibular vertigo. Tinnitus patients needs complexe diagnostic and therapeutic approach, with appropriate time of diagnostic and therapeutic intervention, within 2 months of tinnitus onset . Key words: tinnitus, cerebrovascular disease, betahistine

tinnitus; cerebrovascular disease; betahistine

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

131-x.

2005.

objavljeno

Podaci o matičnoj publikaciji

Neurologia Croatica Proceedings

Barac, Boško

Zagreb:

Podaci o skupu

45 th International Neuropsychiatric Pula Congress

poster

15.06.2005-18.06.2005

Pula, Hrvatska

Povezanost rada

Kliničke medicinske znanosti